Arix Bioscience, a global healthcare and life science company headquartered in London, and Fosun International Limited, announced a strategic agreement to develop and commercialise new clinical therapies for patients.
As part of the agreement, Arix and Fosun will collaborate to invest in and create new companies focused on the development of innovative clinical therapies across a broad range of therapeutic areas, with a particular emphasis on the Chinese market. This is Arix’s third strategic partnership and follows the success of its existing agreements with Takeda Ventures, Inc., and UCB Pharma S.A..
Fosun International Limited is a Chinese investment holding company engaged in healthcare businesses, especially in manufacturing and selling of pharmaceutical products.
Arix will provide Fosun with access to its Group Businesses, pipeline and unique network of key professional and scientific advisors. In turn, Fosun will share potential investment opportunities in China and will have a potential opportunity to promote its services as exclusive distribution partner in China for Arix’s Group Businesses.
Arix Bioscience has privileged agreements with leading universities in the UK, Europe and Australia, providing direct access to innovative new technologies. Company has made investments into 13 innovative life science companies in 2016 and 2017.